Author:
AYDIN Beyza Sultan,BULDUK İbrahim
Publisher
Karamanoglu Mehmetbey University
Reference29 articles.
1. Referans1
Tysnes OB, Storstein A. 2017 Epidemiology of Parkinson’s disease. J Neural Transm. 124(8). 901–905.
2. Referans2
Poewe W, Seppi K, Tanner CM, et al. 2017. Parkinson disease. Nat Rev Dis Primers. 3. 17013-17018
3. Referans3
Kempster PA, Frankel JP, Stern GM, Lees AJ. 1990. Comparison of motor response to apomorphine and levodopa in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 53(11).1004–1007.
4. Referans4
Poewe WH, Lees AJ, Stern GM. 1986. Low-dose L-dopa therapy in Parkinson’s disease: a 6-year follow-up study. Neurology. 36(11).1528–1530.
Referans5
Sweet RD, McDowell FH. 1975. Five years’ treatment of Parkinson’s disease with levodopa. Therapeutic results and survival of 100 patients. Ann Intern Med. 83(4). 456–463.
Referans6
Ernst AM, Smelik PG. 1966. Site of action of dopamine and apomorphine on compulsive gnawing behavior in rats. Experientia. 22(12). 837–8.
5. Referans7
Auffret M, Drapier S, Vérin M. 2018. Pharmacological insights into the use of apomorphine in parkinson’s disease: clinical relevance. Clin Drug Investig. 38(4). 287–312.